Ejection fraction

Ancora Heart Secures $80 Million in Financing

Retrieved on: 
Monday, July 19, 2021

Ancora Heart, Inc ., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing.

Key Points: 
  • Ancora Heart, Inc ., a company developing a novel therapy to address heart failure, today announced it has closed an $80 million equity financing.
  • Ancora Heart is at an exciting stage as we continue with our pivotal clinical trial to support our PMA submission to the FDA, and this investment will help us prepare for potential launch and subsequent commercialization, said Jeff Closs, president and CEO of Ancora Heart.
  • About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency.
  • (ClinicalTrials.gov Identifier: NCT03183895 )
    Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF).

Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction

Retrieved on: 
Tuesday, July 6, 2021

When added to the EMPEROR-Reduced trial results, these findings demonstrate empagliflozins efficacy in all forms of heart failure regardless of ejection fraction.

Key Points: 
  • When added to the EMPEROR-Reduced trial results, these findings demonstrate empagliflozins efficacy in all forms of heart failure regardless of ejection fraction.
  • HFpEF has long been the most challenging form of heart failure to treat, said Professor Stefan Anker, Heart Failure Cardiologist at Charit Berlin, Germany, and EMPEROR-Preserved Principal Investigator.
  • Building on previous results from the EMPA-REG-OUTCOME trial, and the EMPEROR-Reduced trial in heart failure with reduced ejection fraction, the EMPEROR-Preserved findings demonstrate that empagliflozin reduces cardiovascular death or hospitalization for heart failure and has the potential to transform the care of people living with heart failure.
  • With the earlier EMPEROR-Reduced trial results, we are confident in the potential of empagliflozin to positively impact the lives of adults across the full spectrum of heart failure.

Israeli Medical Device Startup, Cardiac Success Ltd., Closes US $5.2M Series A Financing

Retrieved on: 
Wednesday, June 23, 2021

The round was joined by an unnamed global strategic leader in structural heart interventions and a group of Israeli angel investors.

Key Points: 
  • The round was joined by an unnamed global strategic leader in structural heart interventions and a group of Israeli angel investors.
  • Despite guidance-directed medical therapy, heart failure continues to be a serious and common health condition that affects millions of patients and carries high rates of rehospitalizations and deaths.
  • Boaz Manash, CEO of Cardiac Success, said, "There are millions of patients who, despite guidance-directed medical therapy, continue to suffer and deteriorate from Heart Failure with Reduced Ejection Fraction (HFrEF)."
  • Cardiac Success Board chairman and Alon Medtech founder, Shimon Eckhouse, added: "Cardiac Success started in our Alon-Medtech Ventures group a few years ago with a high-risk concept based on out-of-the-box thinking of its founders.

Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction

Retrieved on: 
Monday, June 21, 2021

We are delighted to now be able to offer Jardiance to people with heart failure with reduced ejection fraction, regardless of diabetes status.

Key Points: 
  • We are delighted to now be able to offer Jardiance to people with heart failure with reduced ejection fraction, regardless of diabetes status.
  • This trial will explore empagliflozin in heart failure with preserved ejection fraction, in adults with or without diabetes, continued Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly.
  • There are two forms of the condition; heart failure with reduced ejection fraction means the heart cannot contract normally, while preserved ejection fraction means the heart cannot properly fill with blood.
  • The EMPEROR (EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure) heart failure studies are two Phase III, randomized, double-blind trials investigating once-daily empagliflozin compared with placebo in adults with heart failure with preserved or reduced ejection fraction, with or without diabetes, who are receiving current standard of care:

CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fraction

Retrieved on: 
Friday, May 21, 2021

b'This press release features multimedia.

Key Points: 
  • b'This press release features multimedia.
  • Key secondary endpoint analyses from the trial demonstrated that empagliflozin reduced the relative risk of first and recurrent hospitalization for heart failure by 30 percent and significantly slowed kidney function decline.4\n\xe2\x80\x9cWe are delighted with the CHMP\xe2\x80\x99s decision to recommend empagliflozin as a treatment for people living with symptomatic chronic heart failure with reduced ejection fraction,\xe2\x80\x9d said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim.
  • \xe2\x80\x9cToday\xe2\x80\x99s decision marks our entrance into a new chapter of heart failure management, enabling us to help address the challenges heart failure patients are facing in the EU and beyond.\xe2\x80\x9d\n\xe2\x80\x9cLater this year, we expect trial results from our study in people with heart failure with preserved ejection fraction, another serious form of the condition.
  • People with heart failure often experience breathlessness and fatigue, which can severely impact their quality of life.7,8\nThe EMPEROR-Reduced trial is part of the EMPOWER clinical program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of people across the spectrum of cardio-renal-metabolic conditions.\nThe EMPEROR (EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure) heart failure studies are two Phase III, randomized, double-blind trials investigating once-daily empagliflozin compared with placebo in adults with heart failure with preserved or reduced ejection fraction, both with and without diabetes, who are receiving current standard of care:\n'

Quantum Genomics Will Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting

Retrieved on: 
Wednesday, April 21, 2021

b'PARIS, April 21, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, will present top-line results from its QUORUM study of firibastat in heart failure post myocardial infarction at the European Society of Cardiology (ESC) meeting in August 2021.

Key Points: 
  • b'PARIS, April 21, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, will present top-line results from its QUORUM study of firibastat in heart failure post myocardial infarction at the European Society of Cardiology (ESC) meeting in August 2021.
  • The primary endpoint is the change from baseline in Left Ventricle Ejection Fraction (LVEF) assessed by Cardiac Magnetic Resonance (CMR) after a three-month treatment.
  • Gilles Montalescot, lead investigator of the QUORUM trial commented: \xe2\x80\x9cWe are pleased to present the results of the QUORUM study in August.
  • Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Retrieved on: 
Tuesday, February 16, 2021

For the first time, there is a treatment with benefit for patients diagnosed with guideline-defined heart failure that includes both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3.

Key Points: 
  • For the first time, there is a treatment with benefit for patients diagnosed with guideline-defined heart failure that includes both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3.
  • Approximately 6 million Americans are living with chronic heart failure (CHF)4.
  • In the United States, Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1.
  • Accessed July 2019. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info...
    Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure.

OM1 Heart Failure Registry Reaches More than 140,000 Patients Prospectively Followed with Deep Clinical Data

Retrieved on: 
Thursday, January 28, 2021

BOSTON, Jan. 28, 2021 /PRNewswire/ -- OM1 , a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of an expanded Heart Failure registry.

Key Points: 
  • BOSTON, Jan. 28, 2021 /PRNewswire/ -- OM1 , a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of an expanded Heart Failure registry.
  • Contributing risk factors include diabetes, hypertension, and obesity, all of which are on the rise and further exacerbate poor quality of life and prognosis.
  • The OM1 Heart Failure Registry is a continually updating database of more than 140,000 patients prospectively followed that enables faster access to longitudinal, research-grade data.
  • The registry is geographically and demographically representative and includes deep clinical data, such as left ventricular ejection fraction (LVEF) measures, NYHA functional status, lab results, and medication data.

Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure

Retrieved on: 
Tuesday, October 20, 2020

Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicells lead therapeutic, Zofin, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.

Key Points: 
  • Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicells lead therapeutic, Zofin, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.
  • HFpEF, or diastolic heart failure , is a complex inflammatory disease in which the heart is unable to receive and pump adequate blood to meet the bodys needs.
  • RCN, under the leadership of its Medical Director, Dr. Vincent Friedewald, has extensive experience in managing patients with all forms of heart failure, including the large and growing population of patients with HFpEF.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

Retrieved on: 
Wednesday, October 14, 2020

The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella -supported high-risk PCI, is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at follow up.

Key Points: 
  • The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella -supported high-risk PCI, is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at follow up.
  • (see figure 1)
    Restore EF demonstrates Impella-supported PCI patients have shown a significant LVEF improvement at 90 days.
  • Restore EF is part of a growing body of evidence demonstrating Protected PCI with Impella is associated with improvements in LVEF and heart failure symptoms.
  • Findings from Restore EF will be used to inform the study protocol for the upcoming PROTECT IV Randomized Controlled Trial .